|
US6613785B2
(en)
|
1998-07-21 |
2003-09-02 |
Smithkline Beecham Plc |
Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
|
|
CA2432578C
(en)
|
2001-01-02 |
2008-04-01 |
F. Hoffmann-La Roche Ag |
Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
|
|
US7105667B2
(en)
|
2001-05-01 |
2006-09-12 |
Bristol-Myers Squibb Co. |
Fused heterocyclic compounds and use thereof
|
|
WO2002088079A2
(en)
|
2001-05-01 |
2002-11-07 |
Bristol-Myers Squibb Company |
Dual inhibitors of pde 7 and pde 4
|
|
US20040043434A1
(en)
|
2002-06-13 |
2004-03-04 |
Gen-Sheng Feng |
Shp-2 tyrosine phosphatase and embryonic stem cell differentiation
|
|
WO2004041216A2
(en)
|
2002-11-05 |
2004-05-21 |
Mount Sinai School Of Medicine Of New York University ; |
Ptpn11 (shp-2) mutations and cancer
|
|
WO2005094314A2
(en)
|
2004-03-26 |
2005-10-13 |
The Burnham Institute |
Modulators of shp2 tyrosine phosphatase and their use in the treatment of body weight disorders
|
|
EP1728790A1
(en)
|
2005-06-01 |
2006-12-06 |
Max-Delbrück-Centrum Für Molekulare Medizin |
Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases
|
|
US20080051387A1
(en)
|
2006-06-09 |
2008-02-28 |
Yuelian Xu |
Tetrahydropyrido[3,4-d]pyrimidines and related analogues
|
|
US7547760B2
(en)
|
2006-07-03 |
2009-06-16 |
West Virginia University |
Peptides and chemical compound for inhibition of SHP2 function
|
|
WO2008009078A2
(en)
|
2006-07-20 |
2008-01-24 |
Gilead Sciences, Inc. |
4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
|
|
US20100210649A1
(en)
|
2006-12-21 |
2010-08-19 |
Sloan-Kettering Institute For Cancer Research |
Pyridazinones and furan-containing compounds
|
|
WO2008103470A2
(en)
|
2007-02-21 |
2008-08-28 |
Trustees Of Columbia University In The City Of New York |
Oncogenic-ras-signal dependent lethal compounds
|
|
WO2009047255A1
(en)
|
2007-10-09 |
2009-04-16 |
Ucb Pharma, S.A. |
Heterobicyclic compounds as histamine h4-receptor antagonists
|
|
WO2010011666A2
(en)
|
2008-07-21 |
2010-01-28 |
University Of South Florida |
Indoline scaffold shp-2 inhibitors and cancer treatment method
|
|
US8163763B2
(en)
|
2008-07-31 |
2012-04-24 |
Genentech, Inc. |
Pyrimidine compounds, compositions and methods of use
|
|
WO2010120996A1
(en)
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
|
|
AU2010239188B2
(en)
|
2009-04-22 |
2016-03-31 |
Janssen Pharmaceutica Nv |
Azetidinyl diamides as monoacylglycerol lipase inhibitors
|
|
US20130029978A1
(en)
|
2009-12-25 |
2013-01-31 |
Mochida Pharmaceutical Co., Ltd. |
Novel aryl urea derivative
|
|
WO2011082285A1
(en)
|
2009-12-30 |
2011-07-07 |
Avila Therapeutics, Inc. |
Ligand-directed covalent modification of protein
|
|
NL2008335A
(en)
|
2011-04-07 |
2012-10-09 |
Asml Netherlands Bv |
Lithographic apparatus, device manufacturing method, and method of correcting a mask.
|
|
WO2013155223A1
(en)
|
2012-04-10 |
2013-10-17 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
|
US9695133B2
(en)
|
2012-07-13 |
2017-07-04 |
The Trustees Of Columbia University In The City Of New York |
Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
|
|
KR102373193B1
(ko)
|
2012-11-21 |
2022-03-10 |
얀센 바이오테크 인코포레이티드 |
이중특이성 EGFR/c-Met 항체
|
|
WO2014143659A1
(en)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the gtpase k-ras g12c
|
|
TW201524952A
(zh)
|
2013-03-15 |
2015-07-01 |
Araxes Pharma Llc |
Ｋｒａｓ ｇ１２ｃ之共價抑制劑
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
MX380928B
(es)
|
2013-10-10 |
2025-03-12 |
Araxes Pharma Llc |
Inhibidores de kras g12c.
|
|
WO2015107494A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
ES2699351T3
(es)
|
2014-01-17 |
2019-02-08 |
Novartis Ag |
Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
|
|
EP3148981A4
(en)
|
2014-05-30 |
2017-11-08 |
The Trustees of Columbia University in the City of New York |
Multivalent ras binding compounds
|
|
WO2016025650A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
US10011600B2
(en)
|
2014-09-25 |
2018-07-03 |
Araxes Pharma Llc |
Methods and compositions for inhibition of Ras
|
|
WO2016049565A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Compositions and methods for inhibition of ras
|
|
US9862701B2
(en)
|
2014-09-25 |
2018-01-09 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10017540B2
(en)
|
2015-03-11 |
2018-07-10 |
California Institute Of Technology |
Cyclic peptide binder against oncogenic K-Ras
|
|
AU2016245864C1
(en)
|
2015-04-10 |
2021-09-09 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
ES2856880T3
(es)
|
2015-04-15 |
2021-09-28 |
Araxes Pharma Llc |
Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
WO2016172692A1
(en)
|
2015-04-24 |
2016-10-27 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Mutant kras inhibitors
|
|
AU2016258192B2
(en)
|
2015-05-06 |
2021-07-29 |
Leidos Biomedical Research, Inc. |
K-Ras modulators
|
|
WO2016196591A1
(en)
|
2015-06-01 |
2016-12-08 |
Indiana University Research & Technology Corporation |
Protein tyrosine phosphatases or shp2 inhibitors and uses thereof
|
|
WO2016203406A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
|
ES2824576T3
(es)
|
2015-06-19 |
2021-05-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
|
US10256121B2
(en)
|
2015-07-06 |
2019-04-09 |
Tokyo Electron Limited |
Heated stage with variable thermal emissivity method and apparatus
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
HK1251624A1
(zh)
|
2015-09-24 |
2019-02-01 |
Ionis Pharmaceuticals, Inc. |
Kras表达的调节剂
|
|
US10975071B2
(en)
|
2015-09-28 |
2021-04-13 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
JP2018533939A
(ja)
|
2015-10-19 |
2018-11-22 |
アラクセス ファーマ エルエルシー |
Ｒａｓの阻害剤をスクリーニングするための方法
|
|
US10670605B2
(en)
|
2015-10-22 |
2020-06-02 |
The Scripps Research Institute |
Cysteine reactive probes and uses thereof
|
|
WO2017080980A1
(en)
|
2015-11-09 |
2017-05-18 |
Astrazeneca Ab |
Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer
|
|
WO2017079864A1
(en)
|
2015-11-12 |
2017-05-18 |
Hangzhou Yier Biotech Co., Ltd. |
Treatment of cancers related to chronically active ras
|
|
KR102932353B1
(ko)
|
2015-11-16 |
2026-02-27 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
WO2017100279A1
(en)
|
2015-12-09 |
2017-06-15 |
West Virginia University |
Chemical compound for inhibition of shp2 function and for use as an anti-cancer agent
|
|
WO2017100546A1
(en)
|
2015-12-09 |
2017-06-15 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
US20170283445A1
(en)
|
2016-04-05 |
2017-10-05 |
University Of South Carolina |
Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
|
|
ES2863873T3
(es)
|
2016-05-18 |
2021-10-11 |
Mirati Therapeutics Inc |
Inhibidores de KRAS G12C
|
|
KR102218333B1
(ko)
|
2016-06-07 |
2021-02-22 |
자코바이오 파마슈티칼스 컴퍼니 리미티드 |
Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
|
|
US10377743B2
(en)
|
2016-10-07 |
2019-08-13 |
Araxes Pharma Llc |
Inhibitors of RAS and methods of use thereof
|
|
MX2019006299A
(es)
|
2016-11-30 |
2019-11-12 |
Bantam Pharmaceutical Llc |
Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas.
|
|
JP2020513403A
(ja)
|
2016-11-30 |
2020-05-14 |
バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ |
置換ピラゾールおよびピロール化合物の使用する方法ならびに過剰増殖性疾患の治療のための方法
|
|
CN110291084A
(zh)
|
2016-12-15 |
2019-09-27 |
加利福尼亚大学董事会 |
用于治疗癌症的组合物和方法
|
|
CR20190338A
(es)
|
2016-12-22 |
2019-09-09 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso
|
|
EP3558979B1
(en)
|
2016-12-22 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
|
|
US10344026B2
(en)
|
2017-01-18 |
2019-07-09 |
Nantbio, Inc. |
Compositions and methods of targeting mutant K-ras
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
US20200385364A1
(en)
|
2017-01-26 |
2020-12-10 |
Araxes Pharma Llc |
Fused n-heterocyclic compounds and methods of use thereof
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
JOP20190186A1
(ar)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
مركب كينازولين
|
|
US11358940B2
(en)
|
2017-04-20 |
2022-06-14 |
The Regents Of The University Of California |
K-Ras modulators
|
|
US10640504B2
(en)
|
2017-09-08 |
2020-05-05 |
Amgen Inc. |
Inhibitors of KRAS G12C and methods of using the same
|
|
CA3082579A1
(en)
|
2017-11-15 |
2019-05-23 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
JP7058718B2
(ja)
|
2018-07-31 |
2022-04-22 |
本田技研工業株式会社 |
電力予測システム、電力予測装置、電力予測方法、プログラム、及び記憶媒体
|
|
CN109413550B
(zh)
|
2018-09-30 |
2021-03-09 |
华为技术有限公司 |
音频播放电路和终端
|
|
JP2022508651A
(ja)
*
|
2018-10-08 |
2022-01-19 |
レヴォリューション・メディスンズ，インコーポレイテッド |
癌を処置するためのｓｈｐ２阻害剤組成物および方法
|
|
CN111193490B
(zh)
|
2018-11-14 |
2025-05-13 |
天津大学 |
散热结构、带散热结构的体声波谐振器、滤波器和电子设备
|
|
WO2020146613A1
(en)
|
2019-01-10 |
2020-07-16 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
|
WO2020163598A1
(en)
|
2019-02-07 |
2020-08-13 |
The Regents Of The University Of California |
Immunophilin-dependent inhibitors and uses thereof
|
|
EP3924687A4
(en)
|
2019-02-11 |
2022-11-02 |
Mesomat Inc. |
SENSING FIBERS FOR STRUCTURAL STRESS MONITORING
|
|
KR102747104B1
(ko)
|
2019-02-18 |
2024-12-27 |
한국과학기술연구원 |
단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
|
|
GB2613715B
(en)
|
2019-02-20 |
2023-12-06 |
Fred Hutchinson Cancer Center |
Binding proteins specific for RAS neoantigens and uses thereof
|
|
GB201902392D0
(en)
|
2019-02-21 |
2019-04-10 |
Cambridge Entpr Ltd |
Modular binding proteins
|
|
WO2020176693A2
(en)
|
2019-02-26 |
2020-09-03 |
Cell Response, Inc. |
Methods for treating map3k8 positive cancers
|
|
WO2020177629A1
(zh)
|
2019-03-01 |
2020-09-10 |
劲方医药科技(上海)有限公司 |
螺环取代的嘧啶并环类化合物，其制法与医药上的用途
|
|
US12117170B2
(en)
|
2019-03-05 |
2024-10-15 |
Questor Technology Inc. |
Gas incinerator system
|
|
ES3010507T3
(en)
|
2019-03-05 |
2025-04-03 |
Astrazeneca Ab |
Fused tricyclic compounds useful as anticancer agents
|
|
EP3941938A1
(en)
|
2019-03-06 |
2022-01-26 |
Dana-Farber Cancer Institute, Inc. |
T cell receptors specific to b-cell maturation antigen for treatment of cancer
|
|
WO2020198125A1
(en)
|
2019-03-22 |
2020-10-01 |
Icahn School Of Medicine At Mount Sinai |
Methods for treating colorectal cancer
|
|
WO2020205473A1
(en)
|
2019-03-29 |
2020-10-08 |
Decerna Pharmaceuticals, Inc. |
Compositions and methods for the treatment of kras associated diseases or disorders
|
|
WO2020205486A1
(en)
|
2019-03-29 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
KR102222693B1
(ko)
|
2019-04-04 |
2021-03-04 |
금정제약 주식회사 |
H-rev107 유래 펩타이드의 신규한 용도
|
|
WO2020214537A1
(en)
|
2019-04-15 |
2020-10-22 |
Tosk, Inc. |
Modulators of ras gtpase
|
|
US20200335182A1
(en)
|
2019-04-16 |
2020-10-22 |
Uratim Ltd. |
Method and apparatus for facilitating the binding of biological macromolecules with the use of gluing molecular agents with applications in RAS mutations and related conditions
|
|
EP3964516A4
(en)
|
2019-04-28 |
2023-01-11 |
Genfleet Therapeutics (Shanghai) Inc. |
OXAAZACHUINAZOLINE-7( 8H)-KETONE COMPOUND, PROCESS FOR ITS PRODUCTION AND ITS PHARMACEUTICAL APPLICATION
|
|
HRP20231310T1
(hr)
|
2019-05-10 |
2024-02-02 |
Deciphera Pharmaceuticals, Llc |
Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
|
|
HUE065486T2
(hu)
|
2019-05-10 |
2024-05-28 |
Deciphera Pharmaceuticals Llc |
Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
|
|
EP4563150A3
(en)
|
2019-05-13 |
2025-07-23 |
Novartis AG |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
MY208668A
(en)
|
2019-05-14 |
2025-05-23 |
Janssen Biotech Inc |
Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
|
|
CA3141604A1
(en)
|
2019-05-20 |
2020-11-26 |
1200 Pharma Llc |
Kras g12c inhibitors and uses thereof
|
|
WO2020234103A1
(en)
|
2019-05-21 |
2020-11-26 |
Bayer Aktiengesellschaft |
Identification and use of kras inhibitors
|
|
EP3972973A1
(en)
|
2019-05-21 |
2022-03-30 |
Amgen Inc. |
Solid state forms
|
|
US12252486B2
(en)
|
2019-05-21 |
2025-03-18 |
Amgen Inc. |
Solid state forms
|
|
BR112021023136A2
(pt)
|
2019-05-21 |
2022-01-04 |
Inventisbio Co Ltd |
Compostos heterocíclicos, métodos de preparação e usos dos mesmos
|
|
CA3142404A1
(en)
|
2019-06-07 |
2020-12-10 |
Emory University |
Kras g12v mutant binds to jak1, inhibitors, pharmaceutical compositions, and methods related thereto
|
|
US20220304984A1
(en)
|
2019-06-12 |
2022-09-29 |
Vanderbilt University |
Amino acid transport inhibitors and the uses thereof
|
|
WO2020252336A1
(en)
|
2019-06-12 |
2020-12-17 |
Vanderbilt University |
Dibenzylamines as amino acid transport inhibitors
|
|
WO2021000885A1
(zh)
|
2019-07-01 |
2021-01-07 |
江苏恒瑞医药股份有限公司 |
喹唑啉酮类衍生物、其制备方法及其在医药上的应用
|
|
IL290276B2
(en)
|
2019-08-02 |
2026-05-01 |
Shanghai Jemincare Pharmaceuticals Co Ltd |
Tetracyclic compounds, method for their preparation and use
|
|
US20210040089A1
(en)
|
2019-08-07 |
2021-02-11 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitors
|
|
CN114174298B
(zh)
|
2019-08-14 |
2023-08-01 |
正大天晴药业集团南京顺欣制药有限公司 |
哒嗪酮并嘧啶类衍生物及其医药用途
|
|
CN112390797A
(zh)
|
2019-08-15 |
2021-02-23 |
微境生物医药科技(上海)有限公司 |
新型螺环类K-Ras G12C抑制剂
|
|
CN114222743A
(zh)
|
2019-08-16 |
2022-03-22 |
劲方医药科技(上海)有限公司 |
氧代六元环并嘧啶类化合物，其制法与医药上的用途
|
|
CN119454706A
(zh)
|
2019-08-22 |
2025-02-18 |
密歇根大学董事会 |
治疗kras相关癌症的方法
|
|
CN114269735B
(zh)
|
2019-08-26 |
2024-02-23 |
南京创济生物医药有限公司 |
二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
|
|
CN114615981B
(zh)
|
2019-08-29 |
2024-04-12 |
米拉蒂治疗股份有限公司 |
Kras g12d抑制剂
|
|
JP2022554042A
(ja)
|
2019-09-06 |
2022-12-28 |
ウェルマーカー・バイオ・カンパニー・リミテッド |
バイオマーカー型治療用組成物
|
|
CN114616232B
(zh)
|
2019-09-06 |
2026-05-05 |
正大天晴药业集团南京顺欣制药有限公司 |
氮杂环庚烷并嘧啶类衍生物及其医药用途
|
|
US20220331401A1
(en)
|
2019-09-10 |
2022-10-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating kras mutant cancers
|
|
TW202124374A
(zh)
|
2019-09-13 |
2021-07-01 |
美商拜歐斯瑞克斯公司 |
Ras蛋白降解劑、其醫藥組合物及其治療應用
|
|
US20220402916A1
(en)
|
2019-09-18 |
2022-12-22 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
CN116947885B
(zh)
|
2019-09-20 |
2026-01-23 |
上海济煜医药科技股份有限公司 |
稠合吡啶酮类化合物及其制备方法和应用
|
|
CN114502165A
(zh)
|
2019-09-23 |
2022-05-13 |
苏州浦合医药科技有限公司 |
Shp2抑制剂及其用途
|
|
CN114761012B
(zh)
|
2019-09-24 |
2025-03-21 |
米拉蒂治疗股份有限公司 |
组合疗法
|
|
US20210094919A1
(en)
|
2019-09-25 |
2021-04-01 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitors
|
|
CN114929706A
(zh)
|
2019-09-29 |
2022-08-19 |
百济神州有限公司 |
Kras g12c的抑制剂
|
|
CN112574224A
(zh)
|
2019-09-30 |
2021-03-30 |
上海迪诺医药科技有限公司 |
Kras g12c抑制剂及其应用
|
|
US20230257374A1
(en)
|
2019-10-10 |
2023-08-17 |
Innovent Biologics (Suzhou) Co., Ltd. |
Novel kras g12c protein inhibitor, preparation method therefor, and use thereof
|
|
US20240139193A1
(en)
|
2019-10-15 |
2024-05-02 |
Amgen Inc. |
Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
|
|
JP6754125B1
(ja)
|
2019-10-15 |
2020-09-09 |
学校法人東京理科大学 |
Ｂｒａｐ２作用増強剤
|
|
CN112694475B
(zh)
|
2019-10-23 |
2025-09-23 |
苏州泽璟生物制药股份有限公司 |
环烷基类和杂环烷基类抑制剂及其制备方法和应用
|
|
WO2021080359A1
(ko)
|
2019-10-23 |
2021-04-29 |
에스케이바이오팜 주식회사 |
바이사이클릭 화합물 및 이의 용도
|
|
AU2020369569B2
(en)
|
2019-10-24 |
2026-06-18 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
|
|
MD4051678T2
(en)
|
2019-10-28 |
2026-07-31 |
Merck Sharp & Dohme Llc |
Small molecule inhibitors of the KRAS G12C mutant
|
|
BR112022008375A2
(pt)
|
2019-10-30 |
2022-07-12 |
Genfleet Therapeutics Shanghai Inc |
Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste
|
|
WO2021084765A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd |
4-aminobut-2-enamide derivatives and salts thereof
|
|
WO2021085653A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
MX2022005359A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
|
CN113286794B
(zh)
|
2019-11-04 |
2024-03-12 |
北京加科思新药研发有限公司 |
Kras突变蛋白抑制剂
|
|
CN121471132A
(zh)
|
2019-11-04 |
2026-02-06 |
锐新医药公司 |
Ras抑制剂
|
|
WO2021091956A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN112778301A
(zh)
|
2019-11-07 |
2021-05-11 |
苏州泽璟生物制药股份有限公司 |
四氢吡啶并嘧啶类抑制剂及其制备方法和应用
|
|
EP4043478A4
(en)
|
2019-11-07 |
2024-01-03 |
Chugai Seiyaku Kabushiki Kaisha |
CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION
|
|
WO2021093758A1
(zh)
|
2019-11-15 |
2021-05-20 |
四川海思科制药有限公司 |
一种嘧啶并环衍生物及其在医药上的应用
|
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
WO2021104431A1
(zh)
|
2019-11-29 |
2021-06-03 |
苏州信诺维医药科技股份有限公司 |
Kras g12c抑制剂化合物及其用途
|
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
EP4015520B1
(en)
|
2019-12-02 |
2025-02-19 |
280 Bio, Inc. |
Oxygen-containing heterocyclic compound, preparation method and application thereof
|
|
WO2021113595A1
(en)
|
2019-12-06 |
2021-06-10 |
Beta Pharma, Inc. |
Phosphorus derivatives as kras inhibitors
|
|
WO2021120045A1
(en)
|
2019-12-18 |
2021-06-24 |
InventisBio Co., Ltd. |
Heterocyclic compounds, preparation methods and uses thereof
|
|
WO2021126799A1
(en)
|
2019-12-18 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Macrocyclic peptides as potent inhibitors of k-ras g12d mutant
|
|
CA3165238A1
(en)
|
2019-12-19 |
2021-06-24 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitors
|
|
WO2021121397A1
(zh)
|
2019-12-19 |
2021-06-24 |
首药控股(北京)股份有限公司 |
取代的炔基杂环化合物
|
|
CN114761408B
(zh)
|
2019-12-19 |
2023-09-15 |
贝达药业股份有限公司 |
Kras g12c抑制剂及其在医药上的应用
|
|
CA3164995A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
TR201920922A2
(tr)
|
2019-12-20 |
2020-06-22 |
Ankara Ueniversitesi |
3/4-((2E,6E)-3,7,11-Trimetildodeka-2,6,10-trieniltiyo)benzamid Türevi Bileşikler
|
|
CN113045565A
(zh)
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
|
AU2020414943A1
(en)
|
2019-12-27 |
2022-08-04 |
Wigen Biomedicine Technology (shanghai) Co., Ltd. |
Spiro ring-containing quinazoline compound
|
|
WO2021139678A1
(zh)
|
2020-01-07 |
2021-07-15 |
广州百霆医药科技有限公司 |
吡啶并嘧啶类kras g12c突变蛋白抑制剂
|
|
WO2021139748A1
(en)
|
2020-01-08 |
2021-07-15 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Spirocyclic tetrahydroquinazolines
|
|
WO2021142252A1
(en)
|
2020-01-10 |
2021-07-15 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
EP4092026A4
(en)
|
2020-01-13 |
2024-03-06 |
Suzhou Zelgen Biopharmaceutical Co., Ltd. |
ARYL OR HETEROARYL PYRIDONE OR PYRIMIDINE DERIVATIVES, PRODUCTION METHOD AND USE THEREOF
|
|
KR102396930B1
(ko)
|
2020-01-15 |
2022-05-12 |
한국과학기술연구원 |
피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
|
|
KR102382613B1
(ko)
|
2020-01-15 |
2022-04-06 |
한국과학기술연구원 |
단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물
|
|
WO2021150613A1
(en)
|
2020-01-20 |
2021-07-29 |
Incyte Corporation |
Spiro compounds as inhibitors of kras
|
|
WO2021147967A1
(zh)
|
2020-01-21 |
2021-07-29 |
南京明德新药研发有限公司 |
作为kras抑制剂的大环类化合物
|
|
GB202001344D0
(en)
|
2020-01-31 |
2020-03-18 |
Redx Pharma Plc |
Ras Inhibitors
|
|
US20230099858A1
(en)
|
2020-02-20 |
2023-03-30 |
Beta Pharma, Inc. |
Pyridopyrimidine derivatives as kras inhibitors
|
|
TW202140450A
(zh)
|
2020-02-24 |
2021-11-01 |
大陸商泰勵生物科技（上海）有限公司 |
用於癌症治療的ｋｒａｓ抑制劑
|
|
EP4112606A4
(en)
|
2020-02-24 |
2024-04-10 |
Shanghai Zheye Biotechnology Co., Ltd. |
Aromatic compound and use thereof in preparing antineoplastic drugs
|
|
WO2021173923A1
(en)
|
2020-02-28 |
2021-09-02 |
Erasca, Inc. |
Pyrrolidine-fused heterocycles
|
|
CN114901663B
(zh)
|
2020-03-02 |
2024-07-02 |
上海喆邺生物科技有限公司 |
一类芳香杂环类化合物及其在药物中的应用
|
|
US20230099204A1
(en)
|
2020-03-03 |
2023-03-30 |
Wellmarker Bio Co., Ltd. |
Pharmaceutical composition for prevention or treatment of cancer in which kras mutation and activated ron are present
|
|
CN115397413A
(zh)
|
2020-03-05 |
2022-11-25 |
密歇根大学董事会 |
Egfr、kras、braf和其他靶标的抑制剂及其用途
|
|
IL296091A
(en)
|
2020-03-05 |
2022-11-01 |
Univ Michigan Regents |
Inhibitors of braf, kras, egfr and other targets and their uses
|
|
CN115298174B
(zh)
|
2020-03-12 |
2023-11-03 |
德昇济医药(无锡)有限公司 |
嘧啶并杂环类化合物及其应用
|
|
TW202144345A
(zh)
|
2020-03-17 |
2021-12-01 |
大陸商北京加科思新藥研發有限公司 |
Ｋｒａｓ突變蛋白抑制劑
|
|
US12391692B2
(en)
|
2020-03-25 |
2025-08-19 |
Wigen Boimedicine Technology (Shanghai) Co., Ltd. |
Spiro ring-containing quinazoline compound
|
|
AU2021248363B2
(en)
|
2020-04-03 |
2024-02-15 |
Medshine Discovery Inc. |
Octahydropyrazinodiazanaphthyridine dione compounds
|
|
US20220370416A1
(en)
|
2020-04-06 |
2022-11-24 |
Arvinas Operations, Inc. |
Compounds and methods for targeted degradation of kras
|
|
WO2021203768A1
(zh)
|
2020-04-08 |
2021-10-14 |
江苏恒瑞医药股份有限公司 |
嘧啶并二环类衍生物、其制备方法及其在医药上的应用
|
|
CN121270550A
(zh)
|
2020-04-16 |
2026-01-06 |
因赛特公司 |
稠合三环kras抑制剂
|
|
WO2021216770A1
(en)
|
2020-04-22 |
2021-10-28 |
Accutar Biotechnology Inc. |
Substituted tetrahydroquinazoline compounds as kras inhibitors
|
|
US20230242586A1
(en)
|
2020-04-23 |
2023-08-03 |
The Regents Of The University Of California |
Ras inhibitors and uses thereof
|
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
CN115151532B
(zh)
|
2020-04-29 |
2023-06-06 |
北京泰德制药股份有限公司 |
喹喔啉二酮衍生物作为kras g12c突变蛋白的不可逆抑制剂
|
|
EP4144732A4
(en)
|
2020-04-29 |
2024-05-01 |
Shanghai Ringene BioPharma Co., Ltd. |
BENZOTHIAZOLYL BIARYL COMPOUND, PREPARATION METHOD AND USE THEREOF
|
|
TW202144349A
(zh)
|
2020-04-30 |
2021-12-01 |
大陸商上海科州藥物研發有限公司 |
作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法
|
|
WO2021231526A1
(en)
|
2020-05-13 |
2021-11-18 |
Incyte Corporation |
Fused pyrimidine compounds as kras inhibitors
|
|
CN113666923A
(zh)
|
2020-05-15 |
2021-11-19 |
苏州泽璟生物制药股份有限公司 |
烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
|
|
WO2021236475A1
(en)
|
2020-05-18 |
2021-11-25 |
Asinex Corporation |
Compounds that inhibit asparagine synthetase and their methods of use
|
|
TWI799871B
(zh)
|
2020-05-27 |
2023-04-21 |
大陸商勁方醫藥科技(上海)有限公司 |
三環并環類化合物，其製法與醫藥上的用途
|
|
CA3180314A1
(en)
|
2020-05-29 |
2021-12-02 |
John Graeme HODGSON |
Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
|
|
CN116034106B
(zh)
|
2020-06-02 |
2025-11-04 |
勃林格殷格翰国际有限公司 |
用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
|
|
WO2021245499A1
(en)
|
2020-06-04 |
2021-12-09 |
Pillai Universal Llc |
Novel small molecules for targeted degradation of untargetable kras in cancer therapy
|
|
KR20230019855A
(ko)
|
2020-06-04 |
2023-02-09 |
안텐진 디스커버리 리미티드 |
Kras g12c 단백질의 억제제 및 그의 용도
|
|
WO2021248082A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
WO2021248090A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
WO2021248079A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
WO2021248083A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
US20230026856A1
(en)
|
2020-06-05 |
2023-01-26 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
WO2021252339A1
(en)
|
2020-06-08 |
2021-12-16 |
Accutar Biotechnology, Inc. |
Substituted purine-2,6-dione compounds as kras inhibitors
|
|
WO2021249563A1
(zh)
|
2020-06-12 |
2021-12-16 |
苏州泽璟生物制药股份有限公司 |
芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
|
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2021259331A1
(zh)
|
2020-06-24 |
2021-12-30 |
南京明德新药研发有限公司 |
八元含n杂环类化合物
|
|
WO2022002102A1
(en)
|
2020-06-30 |
2022-01-06 |
InventisBio Co., Ltd. |
Quinazoline compounds, preparation methods and uses thereof
|
|
EP4182313A4
(en)
|
2020-07-16 |
2024-10-09 |
Mirati Therapeutics, Inc. |
KRAS-G12D INHIBITORS
|
|
WO2022017339A1
(zh)
|
2020-07-20 |
2022-01-27 |
江苏恒瑞医药股份有限公司 |
稠合哒嗪类衍生物、其制备方法及其在医药上的应用
|
|
WO2022028346A1
(zh)
|
2020-08-02 |
2022-02-10 |
上海喆邺生物科技有限公司 |
一种芳香类化合物及其在抗肿瘤药物中的应用
|
|
US12655160B2
(en)
|
2020-08-04 |
2026-06-16 |
Mirati Therapeutics, Inc. |
KRAS G12D inhibitors
|
|
WO2022028492A1
(en)
|
2020-08-05 |
2022-02-10 |
Beigene, Ltd. |
Imidazotriazine and pyrrolopyrimidine derivatives as kras g12c inhibitors
|
|
US20230303551A1
(en)
|
2020-08-13 |
2023-09-28 |
Albert Einstein College Of Medicine |
N-cyclyl-sulfonamides useful for inhibiting raf
|